ECA skin disinfectant biocides: EU authorisation 2026 for manufacturers and distributors

Key data

Manufacturers and distributors of skin disinfectant biocidal products operating in the European Union have had a new mandatory reference framework since 31 March 2026. Commission Implementing Regulation (EU) 2026/750 grants the Union authorisation for the biocidal product family ECA Disinfect skin Product family 7, intended specifically for the disinfection of human skin.

This authorisation is granted under Regulation (EU) No 528/2012, the European regulatory framework for the making available on the market and use of biocidal products. The practical result is immediate: the product may be placed on the market in all Member States under harmonised conditions, without the need to process national authorisations country by country.

What does this regulation establish?

Regulation 2026/750 grants a Union authorisation for the biocidal product family ECA Disinfect skin Product family 7. This means the product is enabled for placing on the market and use throughout the EU under a single harmonised regulatory framework.

The key elements established by the regulation are:

• Authorised product: ECA Disinfect skin Product family 7, a biocidal product family whose specific use is the disinfection of human skin.
• Scope of commercialisation: All Member States of the European Union, without the need for additional individual national authorisations.
• Compliance conditions: Manufacturers and distributors must comply with the technical specifications and use restrictions established in the regulation itself.
• Reference regulatory framework: Regulation (EU) No 528/2012 of the European Parliament and of the Council, on the making available on the market and use of biocidal products.

The Union authorisation is the most advanced mechanism in the European biocidal products system: it replaces the national authorisation process in each Member State with a single centralised procedure, reducing administrative burdens and facilitating access to the single market.

Economic and operational impact

For companies that were already placing this type of product on the market or using it under national authorisations, the most relevant operational impact is the simplification of access to the European market. Instead of managing authorisation dossiers in each Member State where they operate, it is sufficient to comply with the conditions set out in Regulation 2026/750.

However, this simplification has a direct counterpart: compliance with the technical specifications and use restrictions established in the authorisation is mandatory throughout the EU from 31 March 2026. Companies that do not adapt their processes, labelling or technical documentation to these conditions may face commercialisation issues in any Member State.

Specific operational impacts include:

• Review of the product's technical documentation to verify alignment with the conditions of the authorisation.
• Update of labelling and safety data sheets where necessary.
• Elimination of national authorisation procedures in the countries where the product was already or is to be placed on the market.
• Potential opportunity to expand into new European markets with a lower administrative burden.

Who is affected?

This regulation directly affects companies and professionals involved in the value chain of skin disinfectant biocidal products in the European Union:

• Manufacturers of the biocidal product family ECA Disinfect skin Product family 7 or equivalent products authorised under this regulation.
• Distributors that place these products on the market in one or more EU Member States.
• Professional users of skin disinfectant biocidal products, especially in environments where use is regulated.
• Companies in the healthcare sector that use human skin disinfectants in their hygiene protocols.
• Companies in the cosmetics and hygiene sector that formulate, package or distribute products of this type.
• Regulatory advisors and compliance officers of companies active in the European biocidal products market.

Practical example

A Spanish distributor that places skin disinfectants on the market in Spain, France and Germany, and that until now operated with national authorisations in each of those countries, can, from Regulation 2026/750 onwards, operate under the single Union authorisation for ECA Disinfect skin Product family 7.

The first step to take is to verify that the product being distributed is effectively included in the authorised family and that it meets the technical specifications and use restrictions set out in the regulation. If so, the company can simplify its regulatory management and, if desired, expand its distribution to other Member States without the need to process new national authorisations.

If the product does not meet any of the established conditions, the company will need to adapt its formulation, labelling or conditions of use before continuing to place it on the market under the umbrella of this authorisation.

What should companies do now?

1. Identify whether the product is included: Verify whether the skin disinfectant biocidal products they manufacture, distribute or use correspond to the ECA Disinfect skin Product family 7 authorised by Regulation 2026/750.
2. Review the technical specifications and use restrictions: Consult the full text of the regulation to check that the product meets all the conditions established in the Union authorisation.
3. Update technical documentation and labelling: If there are new or different conditions from those that applied under previous national authorisations, adapt technical data sheets, safety data sheets and labelling.
4. Assess expansion opportunities: The single authorisation facilitates placing products on the market in all Member States. Consider whether it makes sense to expand into new markets by taking advantage of the administrative simplification.
5. Inform purchasing, quality and regulatory teams: Ensure that internal stakeholders are aware of the new framework and its operational implications from 31 March 2026.

Official source

Disclaimer: This article is for informational purposes only and does not constitute legal advice. For specific decisions, please consult a qualified professional. Source: https://eur-lex.europa.eu/./legal-content/AUTO/?uri=CELEX:32026R0750